Abstract: As a part of our ongoing research in the exploration of novel antimicrobial agents, we report herein novel synthesis of hybrid molecules 4-methyl-7-(2-oxo-2-(5-(substitutedthio)-1,3,4-oxadiazol-2-yl)ethoxy)-2H-chromen-2-ones and 4-substitutedbenzylidene-3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetyl)-1H-pyrazol-5(4H)-ones by combining coumarin ring with 1,3,4-oxadiazole and pyrazole scaffolds respectively. All the synthesized compounds have been characterized by chemical analysis, IR, 1 H NMR, 13 C NMR and mass spectroscopy. All the compounds have been evaluated for their in vitro antimicrobial activity against Staphylococcus aureus, Escherichia coli and fungi Aspergillus niger using serial broth dilution method. All the synthesized compounds displayed antimicrobial activity. Among all the compounds 7c and 7d have been emerged as highly potent molecules with 75 µg/mL potency.
Introduction
Over the years, a wide range of antimicrobial agents have been developed which prolonged the lifespan and eased the affliction of million peoples. But the evolution of antibiotic resistance strains is of principally severe concern due to the biochemical fickleness of several bacteria and the over use of many of these antibiotics. Multidrug resistant bacteria have become a major public health crisis because existing antibiotics are no longer effective in many cases. Considering the rapid advance of multidrug resistance to the existing variety of marketed antibiotics, new approaches are of an immediate need.
It was observed from the literature that certain five membered heterocyclic compounds possess interesting biological activity. Among them the compounds bearing 1,3,4-oxadiazole and pyrazole nucleus have wide applications in medicinal chemistry. A number of oxadiazole derivatives were reported to possess varied biological activities such as anti-Fascinated by the varied biological activity of coumarin, 1,3,4-oxadiazole and pyrazole derivatives it was contemplated to synthesize a new series of 1,3,4-oxadiazoles and pyrazoles carrying coumarin scaffold with a view to kill multidrug resistant bacteria. In our earlier paper we have reported 23 the synthesis and biological evaluation of 2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetohydrazide, 7-((5-mercapto-1,3,4-oxadiazol-2-yl)methoxy)4-methyl-2H-chromen-2-one and 3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy) acetyl)-1H-pyrazol-5(4H)-one. As an extension to this we report herein the synthesis and biological evaluation of 4-methyl-7-(2-oxo-2-(5-(substitutedthio)-1,3,4-oxadiazol-2-yl) ethoxy)-2H-chromen-2-ones and 4-(substitutedbenzylidene)-3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetyl)-1H-pyrazol-5(4H)-ones.
Experimental
All chemicals and reagents were procured from Merck India limited. All reactions except those of aqueous media were carried out by standard techniques with the exclusion of moisture. Melting points were determined in open capillaries on a Mel-Temp apparatus and are uncorrected. The homogeneity of the compounds was checked by TLC (silica gel H, BDH, ethyl acetate-hexane, 3:5) . Column chromatography over silica gel (Merck, 70-230 and 230-400 mesh ASTH for flash chromatography) was applied when necessary to isolate and purity the reaction products. The IR spectra were recorded on Perkin-Elmer spectrum 100 FT-IR spectrometer as KBr pellets. The wave numbers are given in cm -1 . The 1 H NMR spectra were recorded in CDCl 3 /DMSO-d 6 on a jeol JNM λ-400 MHz machine. The 13 C NMR spectra were recorded in CDCl 3 /DMSO-d 6 on a Jeol JNM spectrometer operating at 100 MHz. All chemical shifts are reported in δ (ppm) using TMS as an internal standard. The mass spectra were recorded on VG 7070H mass spectrometer. The micro analyses were performed on Perkin-Elmer 240 C elemental analyzer. 
Synthetic methods and spectroscopic details
A solution of equimolar quantities of resorcinol and ethyl acetoacetate was added drop wise to concentrated sulfuric acid and allowed to stand for 2 h. Then the reaction mixture was poured into a mixture of ice and water with continuous stirring and then neutralized with 40% sodium hydroxide solution. The precipitate formed was filtered, washed with water and recrystallized from ethanol to give 7-hydroxy-4-methyl-2H-chromen-2-one 1. Equimolar quantities of 7-hydroxy-4-methyl-2H-chromen-2-one 1 and ethyl chloroacetate were allowed to react in presence of potassium carbonate for 8 h in dimethylformamide medium to get ethyl 2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetate 2. Compound 2 was further refluxed with hydrazine hydrate in methanol for 8 h to furnish 2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetohydrazide 3. 
2-((4-Methyl-2-oxo-2H-chromen-7-yl)oxy)acetohydrazide, (3)
Yield
Synthesis of 7-((5-mercapto-1,3,4-oxadiazol-2-yl)methoxy)-4-methyl-2H-chromen-2-one (4)
A mixture of 0.01 mol of 2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetohydrazide 3 and 0.01 mol (0.56 g) of KOH and 10 mL of carbon disulphide were refluxed in 50 mL of 95% ethanol for 12 h. The resultant mixture was concentrated and cooled to room temperature. Then it was acidified with dil. HCl. The solid mass thus separated out was filtered, dried and purified by recrystallized from ethanol. Yield 80%; m. 
Synthesis of 4-methyl-7-(2-oxo-2-(5-( yridine-4-ylthio)-1,3,4-oxadiazol-2-yl)ethoxy)-2H-chromen-2-one (5a)
Equimolar quantities of 7-((5-mercapto-1,3,4-oxadiazol-2-yl)methoxy)-4-methyl-2H-chromen-2-one 4 and 4-chloropyridine were refluxed in 95% ethanol for 2 h. The reaction mixture was monitored by TLC until the disappearance of starting materials. The resultant solution was concentrated under reduced pressure. The product was dissolved in ethyl acetate and the organic phase was washed successively with 5% HCl, 5% Na 2 CO 3 solution, water (2x40 mL) and the organic layer was collected, washed with brain solution, dried over Anhy. Na 2 SO 4 and ethyl acetate decanted off. The ethyl acetate was then concentrated under reduced pressure. The solid mass separated out was collected, dried and recrystallized from ethanol to obtain 5a. Compounds 5b-d were similarly obtained, substituting 4-chloropyridine with different chloro compounds. 
4-Methyl-7-(2-oxo-2-(5-(pyridin-4-ylthio)-1,3,4-oxadiazol-2-yl)ethoxy)-2H-chromen-2-one (5a)
4-Methyl-7-(2-oxo-2-(5-(pyridin-2-ylthio)-1, 3, 4-oxadiazol-2-yl)ethoxy)-2H-chromen-2-one (5b)
7-(2-(5-((4-Aminophenyl)thio)-1,3,4-oxadiazol-2-yl)-2-oxoethoxy)-4-methyl-2H-chromen-2-one (5c)
7-(2-(5-((2-Aminophenyl)thio)-1,3,4-oxadiazol-2-yl)-2-oxoethoxy)-4-methyl-2H-chromen-2-one(5d)
Synthesis of 3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetyl)-1H-pyrazol-5(4H)-one(6)
A mixture of ethyl acetoacetate (0.01 mol) and 2-((4-methyl-2-oxo-2H-chromen-7-yl) oxy)acetohydrazide (3) 
Synthesis of 4-benzylidene-3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl) oxy) acetyl)-1H-pyrazol-5(4H)-one(7a)
3-Methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetyl)-1H-pyrazol-5(4H)-one 6 (0.01 mol) and benzaldehyde (0.01 mol) suspended in dry toluene were taken in a flask equipped with a Dean-Stark apparatus fitted with a calcium chloride guard tube. Then catalytic amount of piperidine (0.5 mL) was added and the reaction mixture was refluxed with stirring for about 8 h. The progress of the reaction was monitored by TLC until the disappearance of starting materials. The product precipitated on cooling was washed with methanol and purified by recrystallization from a mixture of ethanol and chloroform (1:1). Compounds 7b-e were prepared similarly, taking appropriate substituted aldehyde in place of benzaldehyde. Methoxybenzylidene)-3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl) 
4-Benzylidene-3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetyl)-1H-pyrazol-5(4H)-one (7a)
4-(4-Chlorobenzylidene)-3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy) acetyl)-1H-pyrazol-5(4H)-one(7b)
4-(4-Hydroxybenzylidene)-3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetyl)-1H-pyrazol-5(4H)-one(7c)
4-(2-Hydroxybenzylidene)-3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy) acetyl)-1H-pyrazol-5(4H)-one(7d)
4-(2-

Results and Discussion
The synthetic strategies adopted to obtain the target compounds are depicted in Scheme 1. One of the precursors 7-((5-mercapto-1,3,4-oxadiazol-2-yl)methoxy)4-methyl-2H-chromen-2-one, 4 was obtained by adopting a simple one pot procedure that involves reacting 2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetohydrazide 3 with carbon disulfide under strong basic conditions followed by acidification with dilute hydrochloric acid. The thiol group was further suitably condensed with different aromatic halo compounds to give the corresponding oxadiazole derivatives 4-methyl-7-(2-oxo-2-(5-(substitutedthio)-1,3,4-oxadiazol-2-yl)ethoxy)-2H-chromen-2-ones 5a-d. Another precursor 3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetyl)-1H-pyrazol-5(4H)-one 6 was obtained by condensing 2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetohydrazide 3 with ethyl acetoacetate in ethanol and refluxing for 8 h. The next step involves Knoevenegel condensation of compounds 6 containing active methylene group with various substituted aromatic aldehydes in presence of catalytic amount of piperidine to yield 4-substitutedbenzylidene-3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetyl)-1H-pyrazol-5(4H)-one 7a-e.
All the synthesized compounds were characterized by chemical analysis, IR, 1 H NMR, 13 C NMR and mass spectroscopy. Compound 3 showed a characteristic absorption band at 3332 cm -1 corresponding to NH stretching and the mass spectrum showed a peak at m/z 249.08 in LCMS due to [M+H] ion corresponding to molecular formula C 12 H 12 N 2 O 4 . Compound 4 showed a characteristic absorption band at 2766 cm -1 corresponding to SH stretching in thiols. The proton NMR spectrum of the compound showed a broad signal at δ 3.32 characteristic of SH proton along with signals for other protons. The absence of these characteristic signal of SH group in compounds 5a-d confirm the successful condensation of compound 4 with aromactic halogeno compounds to furnish the desired target molecules. The proton NMR spectrum of compound 6 showed a signal δ 3.31 corrresponding to the methylene proton of heterocyclic ring. The disappearance of this characteristic signal of methylene group of compound 6 and the appearance of new signal at around δ 6.80 corresponding to the methine proton of Knovenegel adducts along with other characteristic peaks confirms the successful formation of the adducts 7a-e. i) Ethyl chloroacetate, Anhy, K 2 CO 3 , DME ii) Hydrazine hydrate, ethanol iii) CS 2 , KOH, iv) Ethanol v) Ethyl acetoacetate, ethanol vi) Piperidine, Tolune Scheme 1. Synthetic route
Antimicrobial activity
Following common standard strains were used for screening of antibacterial and antifungal activities: Staphylococcus aureus, Escherichia coli and fungi Aspergillus niger. DMSO was used as diluent to get desired concentration of synthesized compounds to test upon standard bacterial strains. Each synthesized compound was diluted for obtaining 2000 µg/mL concentration, as a stock solution. In primary screening 1000 µg/mL concentrations of the synthesized compounds were taken. The synthesized compounds found active in this primary screening were further tested in a second set of dilution against all microorganisms. [19] [20] of the compounds was determined by broth dilution method. The respective clinical strain was spread separately on the Mueller-Hinton broth 21 medium for antibacterial activity and Sabouraud dextrose agar (SDA) broth for antifungal activity. Then 2 µL of test organism suspension was added and incubated at 37 ºC for 24 h for bacteria and 48 h for fungi studies. The drugs Gentamycin and Nystatin were used as standards for comparison of antibacterial and antifungal activities respectively. The minimum inhibitory concentration (MIC) was the lowest concentration of test compound that inhibit the visible growth of the organism and was determined in triplicates. The results are tabulated in Table 1 . From the results presented in Table 1 , it is clear that all the synthesized coumarin derivatives have displayed antimicrobial activity in vitro against Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria and fungi (Aspergillus niger), the MIC raging between 75-100 µg/Ml.
The lowest MIC was 75 µg/Ml for compounds 5b, 7c, 7d and 7e against Staphylococcus aureus and the highest being 100 µg/Ml for compounds 3, 4, 5c, 5d and 6. The MIC for compounds 5a,7a and 7b was 87.5 µg/Ml.
A lowest MIC of 75 µg/Ml was observed with compounds 5a, 5b, 7a, 7c, 7d and 7e against Escherichia coli and the highest MIC was 100 µg/Ml for compound 6. The MIC for compounds 3, 4, 5c, 5d and 7b was 87.5 µg/Ml.
In testing with Aspergillus niger a lowest MIC of 75 µg/mL was observed for compounds 7c, 7d. The highest MIC being 100 µg/mL for compounds 3, 4, 5c and 6. The MIC for compounds 5a, 5b, 5d, 7a, 7b and 7e was 87.5 µg/mL.
Of all the compounds studied, 7c and 7d are found more active exhibiting a MIC of 75 µg/mL against all the strains. The antimicrobial activities are not significantly influenced by variation of substituent in the aromatic rings. The result reveal that the Knovenegel adducts with electron releasing OH group in the phenyl ring exhibit high activity compared to the other compounds under investigation in both antibacterial and antifungal activities. But at the same time all the compounds are found to be less active than the standard compound, Gentamycin. All the compounds show antifungal activity comparable with the standard compound, Nystatin.
Conclusion
The compounds 4-methyl-7-(2-oxo-2-(5-(substitutedthio)-1,3,4-oxadiazol-2-yl)ethoxy)-2H-chromen-2-ones and 4-substitutedbenzylidene-3-methyl-1-(2-((4-methyl-2-oxo-2H-chromen -7-yl)oxy)acetyl)-1H-pyrazol-5(4H)-ones were synthesized by combining coumarin ring with 1,3,4-oxadiazole and pyrazole scaffolds respectively. The spectral data are consistent with the structure of the newly synthesized compounds. The minimum inhibitory concentration (MIC) of the synthesized compounds was studied using broth dilution method. The results revealed that all the compounds synthesized exhibited moderate to good antimicrobial activity.
